Company Overview
- Headquarters
- 1925 Century Park E, Los Angeles CA
- Website
- abcentra.com
- Employees
- 5
- Industry
- BioTech/Drugs
Financials & Stats
Revenue
$3B
Who is Abcentra
Abcentra is a clinical-stage biopharmaceutical company based in Los Angeles, California. Founded with a small team of five employees, Abcentra has generated $2.5 million in revenue. The company is dedicated to developing innovative treatments for patients suffering from coronary artery disease (CAD). Abcentra focuses on bringing new and improved therapies to patients with CAD, aiming to prevent heart attacks. Their core technology centers around targeting oxidized low-density lipoprotein (OxLDL), a novel approach to reduce coronary inflammation. This targeted approach holds the potential for enhanced efficacy and safety compared to other anti-inflammatory therapies currently available. The company's lead product, Orticumab, is a first-in-class monoclonal antibody designed to combat oxidized LDL (OxLDL), a key factor in atherosclerotic disease and heart attacks. Currently, Abcentra is developing Orticumab for secondary prevention of heart-related events following an acute coronary syndrome (ACS). The company's future plans include expanding the use of Orticumab into primary prevention for CAD patients experiencing coronary inflammation. For more information about Abcentra and its groundbreaking therapies, visit their website at abcentra.com.
Abcentra Industry Tags
Companies Similar to Abcentra
Analyze industry trends and opportunities by examining competitors and companies comparable to Abcentra, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 3M | Arvada, CO | |||
| 3M | 6 | Star Valley Ranch, WY | ||
| 3M | 4 | Ann Arbor, MI | 2006 | |
| 3M | 3 | San Diego, CA | ||
| 3M | 3 | New York, NY |